Pascual J
Service of Neurology, University Hospital Marqués de Valdecilla, Santander, Spain.
Curr Med Res Opin. 2001;17 Suppl 1:s63-7. doi: 10.1185/0300799039117011.
In this manuscript we review the key basic and clinical data of almotriptan, the new selective 5-HT(1B/D) agonist developed for the symptomatc treatment of migraine. Among triptans, almotriptan has the highest oral bioavailability, with more than two-thirds of the administered dose absorbed within the first hourboth inside and outside a migraine attack. Gender or the presence of food in the stomach do not influence this pharmacokinetic profile, and its clean metabolism results in no relevant interactions with other medications. The dose exhibiting the best efficacy/ tolerability ratio is 12.5 mg. Efficacy parameters with this dose are very comparable to those of sumatriptan 100 mg, with a recurrence rate in the lower range. The tolerability of almotriptan is similar to that for placebo. The incidence of chest symptoms is very low (<1%), even though this drug remains contraindicated in patients with ischaemic cardiomyopathy. In summary, almotriptan's promising basic profile together with its excellent tolerability/safety profile and good efficacy confirm this new 5-HT(1B/D) agonist as a drug of choice for the symptomatic treatment of migraine attacks.
在本手稿中，我们回顾了阿莫曲坦的关键基础和临床数据。阿莫曲坦是一种新的选择性5-HT(1B/D)激动剂，用于偏头痛的症状性治疗。在曲坦类药物中，阿莫曲坦具有最高的口服生物利用度，在偏头痛发作期间及发作之外，超过三分之二的给药剂量在第一小时内被吸收。性别或胃内是否有食物均不影响这一药代动力学特征，其代谢过程简单，不会与其他药物发生显著相互作用。疗效/耐受性比最佳的剂量为12.5毫克。该剂量的疗效参数与100毫克舒马曲坦的参数非常相似，复发率处于较低范围。阿莫曲坦的耐受性与安慰剂相似。胸部症状的发生率非常低（<1%），尽管该药物在缺血性心肌病患者中仍属禁忌。总之，阿莫曲坦有前景的基础特征、出色的耐受性/安全性特征以及良好的疗效，证实这种新的5-HT(1B/D)激动剂是偏头痛发作症状性治疗的首选药物。
